Chemical stability and physical compatibility of meropenem in admixtures for continuous and extended intravenous infusions.

Enferm Infecc Microbiol Clin (Engl Ed)

Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, (FISABIO), Valencia, Spain. Electronic address:

Published: December 2023

Introduction: Prolonged intravenous infusion of beta-lactams increase the clinical cure rate compared to conventional administration in critical or septic patients. This study aimed to determine chemical stability and physical compatibility of meropenem at conditions used in clinical practice to evaluate the stability of the preparation during its administration and the possibility of anticipated preparation.

Methods: Admixtures in study were: (i) meropenem 6g in 0.9% sodium chloride (NS) in infusor of 2mL/h 50mL or 10mL/h 240mL; (ii) meropenem 1 or 2g in NS in infusion bag of 250mL. Temperatures of study were: (i) infusor: 4.5°C, 32°C or 12h at 4.5°C followed by 32°C; (ii) Infusion bag: 4.5°C, 24.5°C or 6h at 4.5°C followed by 24.5°C. Time of study was 5-6 days in infusor and 1 day in infusion bag. Chemical stability was evaluated by high performance liquid chromatography and physical compatibility by measuring pH and visual inspection.

Results: Chemical stability and physical compatibility of meropenem in admixtures in infusors were reduced at high meropenem concentration and high temperature. Admixtures in infusion bag show chemical stability and physical compatibility for at least 1 day.

Conclusion: Administration of meropenem 6g in infusion of 24h in 240mL of 0.9% NaCl in infusor of 10mL/h could be possible if the admixture is infused at 4.5°C. Extended infusion of meropenem 1 or 2g in 0.9% NaCl in infusion bag (250mL) in 3-4h is also feasible. Anticipated preparation of the admixtures in infusion bag is possible with a stability of 24h.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eimce.2022.07.010DOI Listing

Publication Analysis

Top Keywords

infusion bag
24
chemical stability
20
physical compatibility
20
stability physical
16
compatibility meropenem
12
infusion
9
meropenem
8
meropenem admixtures
8
meropenem 09%
8
meropenem infusion
8

Similar Publications

Introduction: This review aimed to investigate the inadvertent administration of antibiotics via epidural and intrathecal routes. The secondary objective was to identify the contributing human and systemic factors.

Methods: PubMed, Scopus and Google Scholar databases were searched for the last five decades (1973-2023).

View Article and Find Full Text PDF

Background: Sub-Saharan Africa faces one of the highest burdens of venereal diseases (VDs) globally. This review aims to critically evaluate the existing literature on the diverse Indigenous knowledge and medicinal plants utilised for treating VDs in sub-Saharan Africa.

Methods: We used the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) protocol to guide the execution of the review.

View Article and Find Full Text PDF

Most antibiotics administered via intermittent IV infusion are diluted in 50 to 100 ml of diluent. The primary infusion set for the BD Alaris pumps can hold 25 ml of volume in its tubing, potentially contributing up to a 50% drug loss if residual volume is present after administration is complete. In the case of antibiotics, this may lead to significant underdosing, potentially contributing to reduced therapeutic response and emergence of antimicrobial resistance.

View Article and Find Full Text PDF

Efgartigimod: A Review in Generalised Myasthenia Gravis.

Drugs

November 2024

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Efgartigimod (Vyvgart; Vyvgart Hytrulo) is a neonatal fragment crystallizable receptor (FcRn) antagonist indicated for the treatment of generalised myasthenia gravis (gMG) in adults who are acetylcholine receptor (AChR) antibody positive (Ab+). Efgartigimod is approved for both intravenous (IV) and subcutaneous (SC) use. In a pivotal phase III trial, IV efgartigimod was associated with significant and clinically meaningful improvements in myasthenia gravis symptoms and reductions in disease burden.

View Article and Find Full Text PDF
Article Synopsis
  • Perinatal hypoxia-ischaemia in extremely preterm infants leads to long-term neurodevelopmental issues, and while insulin-like growth factor-1 (IGF-1) can help with acute brain injuries, its effects on chronic brain damage are not well understood.
  • In a study with preterm-equivalent fetal sheep, subjects that underwent asphyxia demonstrated significant brain damage, including loss of white matter and inflammation.
  • However, prolonged treatment with IGF-1 after asphyxia improved white matter recovery and reduced inflammation, suggesting it may enhance brain maturation in preterm infants affected by severe asphyxia.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!